The NF-κβ transcription factor is a molecular mediator crucial to many biological functions and a central regulator of inflammatory and immune responses. NF-κβ is activated by multiple immunologically relevant stimuli, including members of the tumor necrosis factor (TNF) superfamily, and targeting TNF/NFκβ activity is a therapeutic objective in many inflammatory and autoimmune conditions. Here, we describe the generation of a transgenic reporter mouse model, expressing the human tumor necrosis factor α (TNF-α) transgene (TNF-tg) and carrying the luciferase gene under control of the NFκB-responsive element (NF-κB-Luc). Bioluminescence imaging shows that overexpression of TNF-α effectively activates NF-κB luciferase in vivo. To evaluate this system as a screen for potential therapeutics targeting the TNF/NFκβ signaling pathway, we treated double mutant mice with PGRN-derived Atsttrin, an engineered molecule comprising the minimal progranulin (PGRN):TNFR binding fragments previously demonstrated as therapeutic in multiple models of TNF/NFκβ-driven disease. Administration of Atsttrin could effectively inhibit luciferase activity in TNF-tg:NF-κB-Luc double mutant mice and demonstrates that this transgenic model can be used to non-invasively monitor the in vivo efficacy of modulators of TNF-activated NF-κB signaling pathway.
Nat Med. 2003 Feb;9(2):225-9
[PMID:
12524533]
Arthritis Res Ther. 2013;15(6):R211
[PMID:
24321127]
Cytokine. 2018 Jan;101:48-55
[PMID:
27527809]
Front Biosci (Landmark Ed). 2014 Jun 01;19:1176-85
[PMID:
24896343]
Mol Endocrinol. 2015 Apr;29(4):528-41
[PMID:
25664864]
J Exp Med. 2010 Jan 18;207(1):117-28
[PMID:
20026663]
Neural Regen Res. 2019 Nov;14(11):1994-2002
[PMID:
31290458]
PLoS One. 2014 Nov 13;9(11):e112110
[PMID:
25393765]
Dig Dis Sci. 2014 Aug;59(8):1733-42
[PMID:
24591016]
J Pathol. 2008 Jan;214(2):149-60
[PMID:
18161752]
Arthritis Rheum. 2010 Jul;62(7):2023-36
[PMID:
20506400]
Science. 2011 Apr 22;332(6028):478-84
[PMID:
21393509]
Immunol Cell Biol. 2014 Apr;92(4):299-300
[PMID:
24518982]
Arthritis Res Ther. 2017 Dec 19;19(1):280
[PMID:
29258611]
Cancer Res. 2002 Oct 1;62(19):5590-6
[PMID:
12359772]
Stem Cells Transl Med. 2015 May;4(5):523-31
[PMID:
25824140]
Cardiovasc Res. 2013 Oct 1;100(1):125-33
[PMID:
23847387]
Trends Mol Med. 2011 Oct;17(10):538-40
[PMID:
21802362]
J Cell Biol. 2008 Apr 7;181(1):37-41
[PMID:
18378771]
Dev Biol. 2000 Jan 15;217(2):406-18
[PMID:
10625564]
Cell. 2002 Dec 13;111(6):867-78
[PMID:
12526812]
Oncotarget. 2017 Nov 29;8(65):109692-109702
[PMID:
29312639]
Cytokine Growth Factor Rev. 2002 Aug-Oct;13(4-5):315-21
[PMID:
12220546]
Pharmacol Ther. 2012 Jan;133(1):124-32
[PMID:
22008260]
Cytokine Growth Factor Rev. 2019 Feb;45:53-64
[PMID:
30733059]
PLoS One. 2013 Sep 30;8(9):e76679
[PMID:
24098801]
Inflammation. 2014 Oct;37(5):1806-13
[PMID:
24803297]
Sci Rep. 2014 Nov 12;4:7023
[PMID:
25387791]
Ann Rheum Dis. 2019 Nov;78(11):1524-1535
[PMID:
31302596]
Sci Rep. 2016 Feb 11;6:20909
[PMID:
26864916]
Ann Rheum Dis. 2015 Dec;74(12):2244-2253
[PMID:
25169730]
Cold Spring Harb Perspect Biol. 2009 Dec;1(6):a001651
[PMID:
20457564]
Immunology. 2015 Jun;145(2):279-87
[PMID:
25626394]
FASEB J. 2017 Apr;31(4):1354-1367
[PMID:
28011648]
J Biol Chem. 2007 Apr 13;282(15):11347-55
[PMID:
17307734]
FEBS Lett. 2013 Jun 19;587(12):1805-10
[PMID:
23669357]
PLoS One. 2014 Mar 20;9(3):e92743
[PMID:
24651300]
Signal Transduct Target Ther. 2017;2:
[PMID:
29158945]
Ann N Y Acad Sci. 2019 Apr;1442(1):5-16
[PMID:
30008173]
